Document:

<PAGE>

                                                                     Exhibit 4.9

      THIS WARRANT, AND THE COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT,
      HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 AS AMENDED, OR
      ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE,
      PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
      STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY
      TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES
      ACT OF 1933 ACT AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS.

                      FIRST AMENDMENT TO WARRANT AGREEMENT

                    To Purchase Shares of the Common Stock of

                         Omrix Biopharmaceuticals, Inc.

      FIRST AMENDMENT, dated as of March 20, 2006 (this "Agreement"), between
Omrix Biopharmaceuticals, Inc., a Delaware corporation (the "Company") and
Asante Partners LLC (the "Warrantholder"), to that certain Warrant Agreement
between the Company and the Warrantholder, dated March 31, 2005 (the "Warrant
Agreement").

      WHEREAS, the Company has engaged the Warrantholder for certain services
under an engagement letter dated July 21, 2004 (the "Engagement Letter");

      WHEREAS, pursuant to the Engagement Letter the Company agreed to issue to
the Warrantholder warrants to purchase shares of the Company common stock with
an aggregate exercise price of $62,500 at the beginning of every quarter of the
Retainer Period as defined in the Engagement Letter;

      WHEREAS, on March 31, 2005 the Company terminated the engagement of the
Warrantholder after two quarters of Retainer Period;

      WHEREAS, pursuant to the Engagement Letter the number of shares into which
such warrants shall be exercised into is $4.18 per share;

         WHEREAS, on March 31, 2005 the Company entered into that certain
Warrant Agreement with the Warrantholder;

      WHEREAS, the Company and the Warrantholder wish to amend and restate the
Warrant Agreement in its entirety, as stated below;

      NOW, THEREFORE:

<PAGE>

      SECTION 1. GRANT OF THE RIGHT TO PURCHASE COMMON STOCK.

      The Company hereby grants to the Warrantholder, and the Warrantholder is
entitled, to subscribe for and purchase, from the Company, up to 29,904 fully
paid and non-assessable shares of the Common Stock (as defined below) at a
purchase price of $4.18 per share (the "Exercise Price"). As used herein, the
following terms shall have the following meanings:

            "Average Closing Price" means, as to the Common Stock, the average
of the closing sales prices as reported by the National Association of
Securities Dealers, Inc. electronic interdealer quotation system ("Nasdaq") on
the Nasdaq SmallCap Market or the Nasdaq National Market System or on such other
domestic securities exchange on which the Common Stock may then be listed, as
applicable, or, if on any day the Common Stock is not quoted in the Nasdaq
National Market System or the Nasdaq SmallCap Market or listed on any domestic
securities exchange, the average of the highest bid and lowest asked prices on
such day in the domestic over-the-counter market as reported by the National
Quotation Bureau, Incorporated, or any similar successor organization, in each
such case for the twenty (20) trading days immediately preceding the date of the
exercise of this Warrant. If at the date of the exercise of this warrant, the
Common Stock is not listed on any domestic securities exchange or quoted in the
Nasdaq National Market System, the Nasdaq SmallCap Market or the domestic
over-the-counter market, the "Average Closing Price" shall be the fair value
thereof determined in good faith by the Company's Board of Directors; provided
that if Warrantholder in good faith disagrees with such valuation, such fair
value shall be determined by an investment banker jointly selected by the
Company and the Warrantholder. The determination of such investment banker shall
be final and binding on the Company and the Warrantholder, and the fees and
expenses of such appraiser shall be shared equally by the Company and the
Warrantholder.

            "Charter" means the Company's Certificate of Incorporation or other
constitutional document, as may be amended from time to time;

            "Common Stock" means the Company's common stock; $0.01 par value per
share;

            "Initial Public Offering" means the initial underwritten public
offering of the Company's Common Stock pursuant to a registration statement
under the 1933 Act, which public offering has been declared effective by the
Securities and Exchange Commission ("SEC");

            "Merger Event" means a merger or consolidation involving the Company
in which the Company is not the surviving entity, or in which the outstanding
shares of the Company's capital stock are otherwise converted into or exchanged
for shares of capital of another entity;

            "1933 Act" means the U.S. Securities Act of 1933, as amended;

            "1934 Act" means the U.S. Securities Exchange Act of 1934, as
amended; and

            "Purchase Price" means, with respect to any exercise of this
Agreement, an amount equal to the Exercise Price as of the relevant time
multiplied by the number of shares of Common Stock requested to be exercised
under this Agreement pursuant to such exercise.

                                       2
<PAGE>

      SECTION 2. TERM.

      Except as otherwise provided for herein, the term of this Agreement and
the right to purchase Common Stock as granted herein (the "Warrant") shall
commence on the date hereof and shall be exercisable for a period ending, with
respect to the right to purchase 14,952 shares of Common Stock on September 30,
2009, and with respect to the right to purchase the remaining 14,952 shares of
Common Stock, on December 31, 2009.

      SECTION 3. EXERCISE OF THE PURCHASE RIGHTS.

            (a) Exercise. The purchase rights set forth in this Agreement are
exercisable by the Warrantholder, in whole or in part, at any time, or from time
to time, prior to the expiration of the term set forth in Section 2, by
tendering to the Company at its principal office (i) a notice of exercise in the
form attached hereto as Exhibit I (the "Notice of Exercise"), duly completed and
executed, with option one or two being chosen as provided therein, and (ii) a
duly completed and executed Stockholder Instrument of Accession in the form
attached hereto as Exhibit IV (the "Instrument of Accession"). Promptly upon
receipt of the Notice of Exercise, the Instrument of Accession and the payment
of the Purchase Price, if the Warrantholder is not choosing a Cashless Exercise
(as defined below), in accordance with the terms set forth below, and in no
event later than three (3) business days thereafter, the Company shall issue to
the Warrantholder a certificate for the number of shares of Common Stock
purchased and shall execute the acknowledgment of exercise in the form attached
hereto as Exhibit II (the "Acknowledgment of Exercise") indicating the number of
shares which remain subject to future purchases, if any.

            (i) Upon choosing option one as provided in the Exercise Agreement,
      the Purchase Price may be paid by the Warrantholder in cash.

            (ii) The Warrantholder's choice of option two as provided in the
      Exercise Agreement (a "Cashless Exercise") and surrender of such Exercise
      Agreement shall be deemed a waiver of the Warrantholder's obligation to
      pay the Purchase Price, or the proportionate part thereof if this Warrant
      is exercised in part. In the event of a Cashless Exercise, the
      Warrantholder shall exchange its Warrant for that number of shares of
      Common Stock which shall be multiplied by a fraction, the numerator of
      which shall be the difference between the then Average Closing Price Per
      Share of Common Stock and the Exercise Price, and the denominator of which
      shall be the then Average Closing Price Per Share of Common Stock.

            (iii) Upon partial exercise the Company shall promptly issue an
      amended Agreement representing the remaining number of shares purchasable
      hereunder. All other terms and conditions of such amended Agreement shall
      be identical to those contained herein, including, but not limited to the
      Effective Date.

      SECTION 4. RESERVATION OF SHARES.

      During the term of this Agreement, the Company will at all times have
authorized and reserved a sufficient number of shares of its Common Stock to
provide for the exercise of the rights to purchase Common Stock as provided for
herein.

                                       3

<PAGE>

      SECTION 5. NO FRACTIONAL SHARES OR SCRIP.

      No fractional shares or scrip representing fractional shares shall be
issued upon the exercise of this Agreement, but in lieu of such fractional
shares the Company shall make a cash payment therefor upon the basis of the
Exercise Price then in effect.

      SECTION 6. NO RIGHTS AS SHAREHOLDER/STOCKHOLDER.

      This Agreement does not entitle the Warrantholder to any voting rights or
other rights as a stockholder of the Company prior to the exercise of the
purchase rights under this Agreement and payment of the applicable Purchase
Price. The Warrantholder acknowledges that the Common Stock issued upon the
exercise of this Agreement shall be subject to any and all limitations and
restrictions set forth in the Company's Charter, then current bylaws, and the
Stockholders Agreement entered into by and between the Company and the
stockholders of the Company dated as of January 13, 2005, as any one or more of
such instruments may be amended from time to time.

      SECTION 7. ADJUSTMENT RIGHTS.

      The Exercise Price and the number of shares of Common Stock purchasable
hereunder are subject to adjustment, as follows:

            (a) Merger Event. If at any time there shall be Merger Event, then,
as a part of such Merger Event, lawful provision shall be made so that the
Warrantholder shall thereafter be entitled to receive, upon exercise of this
Agreement, the number of shares of Common Stock or other securities or property
of the successor corporation resulting from such Merger Event that would have
been issuable if Warrantholder had exercised this Agreement immediately prior to
the Merger Event. In any such case, appropriate adjustment (as determined in
good faith by the Company's Board of Directors) shall be made in the application
of the provisions of this Agreement with respect to the rights and interests of
the Warrantholder after the Merger Event to the end that the provisions of this
Agreement (including adjustments of the Exercise Price and number of shares of
Common Stock purchasable) shall be applicable in their entirety, and to the
greatest extent possible. Without limiting the foregoing, in connection with any
Merger Event, upon the closing thereof, the successor or surviving entity shall
assume the obligations of this Agreement.

            (b) Reclassification of Shares. Except as set forth in Section 7(a),
if the Company at any time shall, by combination, reclassification, exchange or
subdivision of securities or otherwise, change any of the securities as to which
purchase rights under this Agreement exist into the same or a different number
of securities of any other class or classes, this Agreement shall thereafter
represent the right to acquire such number and kind of securities as would have
been issuable as the result of such change with respect to the securities which
were subject to the purchase rights under this Agreement immediately prior to
such combination, reclassification, exchange, subdivision or other change.

            (c) Subdivision or Combination of Shares. If the Company at any time
shall subdivide or combine its Common Stock, including but not limited to any
stock split or reverse stock split, (i) in the case of a subdivision, the
Exercise Price shall be proportionately decreased,

                                       4

<PAGE>

and the number of shares of Common Stock issuable upon exercise of this
Agreement shall be proportionately increased, or (ii) in the case of a
combination, the Exercise Price shall be proportionately increased, and the
number of shares of Common Stock issuable upon the exercise of this Agreement
shall be proportionately decreased.

            (d) Stock Dividends. If the Company at any time while this Warrant
is outstanding and unexpired shall pay a stock dividend with respect to the
Common Stock payable in Common Stock, then the Exercise Price shall be adjusted,
from and after the date of determination of shareholders entitled to receive
such dividend or distribution, to that price determined by multiplying the
Exercise Price in effect immediately prior to such date of determination by a
fraction (A) the numerator of which shall be the total number of shares of
Common Stock outstanding immediately prior to such dividend or distribution, and
(B) the denominator of which shall be the total number of shares of Common Stock
outstanding immediately after such dividend or distribution.

      SECTION 8. REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY.

            (a) Reservation of Common Stock. The Common Stock issuable upon
exercise of the Warrantholder's rights has been duly and validly reserved and,
when issued in accordance with the provisions of this Agreement, will be validly
issued, fully paid and non-assessable, and will be free of any taxes, liens,
charges or encumbrances of any nature whatsoever; provided, that the Common
Stock issuable pursuant to this Agreement may be subject to restrictions on
transfer under state and/or federal securities laws, and subject to any and all
limitations and restrictions set out in the Company's Charter, then current
bylaws, and the Stockholders Agreement entered into by and between the Company
and the holders of the Company's Common Stock dated as of January 13, 2005, as
one or more of such instruments may be amended from time to time.

            (b) Due Authority. The execution and delivery by the Company of this
Agreement and the performance of all obligations of the Company hereunder,
including the issuance to Warrantholder of the right to acquire the shares of
Common Stock, have been duly authorized by all necessary corporate action on the
part of the Company. This Agreement: (1) are not inconsistent with the Company's
Charter or current bylaws; (2) do not contravene any law or governmental rule,
regulation or order applicable to it; and (3) do not and will not contravene any
provision of, or constitute a default under, any indenture, mortgage, contract
or other instrument to which it is a party or by which it is bound. This
Agreement constitutes legal, valid and binding agreements of the Company,
enforceable in accordance with their respective terms.

            (c) Consents and Approvals. No consent or approval of, giving of
notice to, registration with, or taking of any other action in respect of any
state, federal or other governmental authority or agency is required with
respect to the execution, delivery and performance by the Company of its
obligations under this Agreement, except for the filing of notices pursuant to
Regulation D under the 1933 Act and any filing required by applicable state
securities law, which filings will be effective by the time required thereby.

                                       5

<PAGE>

            (d) Exempt Transaction. Subject to and in reliance on the accuracy
of the Warrantholder's representations in Section 9, the issuance of the Common
Stock upon exercise of this Agreement will constitute a transaction exempt from
(i) the registration requirements of Section 5 of the 1933 Act, in reliance upon
Section 4(2) thereof, and (ii) the qualification requirements of the applicable
state securities laws.

            (e) Piggy-Back Registration Rights. If the Company files any
registration statement with the SEC registering for sale any Common Stock of any
other shareholders of the Company, then the Company agrees that so long as the
Common Stock issuable upon exercise of the Warrant is not eligible for sale
pursuant to Rule 144 of the General Rules and Regulations promulgated under the
1933 Act ("Rule 144"), the Company shall include the Common Stock issuable upon
exercise of the Warrant in such registration statement on a pro rata basis with
the other shareholders selling Common Stock in such registration statement. In
addition, the Company agrees to take all action reasonably requested by the
Warrantholder to permit the transfer of Common Stock issuable upon exercise of
the Warrant pursuant to Rule 144 at such time as Rule 144 becomes available to
the Warrantholder for this purpose.

      SECTION 9. REPRESENTATIONS AND COVENANTS OF THE WARRANTHOLDER.

      This Agreement has been entered into by the Company in reliance upon the
following representations and covenants of the Warrantholder, which the
Warrantholder acknowledges will be confirmed pursuant to Exhibit 1 upon each
exercise of this Warrant, in whole or in part:

            (a) Investment Purpose. The right to acquire Common Stock and the
Common Stock issuable upon exercise of the Warrantholder's rights contained
herein will be acquired for investment and not with a view to the sale or
distribution of any part thereof, and the Warrantholder has no present intention
of selling or engaging in any public distribution of the same except pursuant to
a registration or exemption.

            (b) Private Issue. The Warrantholder understands that (i) the Common
Stock issuable upon exercise of this Agreement is not registered under the 1933
Act or qualified under applicable state securities laws on the ground that the
issuance contemplated by this Agreement will be exempt from the registration and
qualifications requirements thereof, and (ii) the Company's reliance on such
exemption is predicated on the representations set forth in this Section 9.

            (c) Disposition of Warrantholder's Rights. In no event will the
Warrantholder make a disposition of any of its rights to acquire Common Stock or
Common Stock issuable upon exercise of such rights, unless and until (i) it
shall have received the Company's written consent to such disposition, and (ii)
if requested by the Company, it shall have furnished the Company with an opinion
of counsel (which counsel may either be inside or outside counsel to the
Warrantholder) satisfactory in form and substance to the Company and its counsel
to the effect that (A) a registration statement in effect with respect to such
disposition, no stop order has been issued nor are any proceedings pending or
threatened for the issuance of any stop order with respect to such registration
statement, and all other appropriate action necessary for compliance with the
1933 Act has been taken, or (B) an exemption from the registration

                                       6

<PAGE>

requirements of the 1933 Act is available. Notwithstanding the foregoing, the
restrictions imposed upon the transferability of any of its rights to acquire
Common Stock or Common Stock issuable on the exercise of such rights do not
apply to transfers from the beneficial owner of any of the aforementioned
securities to its nominee or from such nominee to its beneficial owner, and such
restrictions shall terminate as to any particular share of Common Stock when (1)
such security shall have been effectively registered under the 1933 Act and sold
by the holder thereof in accordance with such registration or (2) such security
shall have been sold without registration in compliance with Rule 144, or (3) a
letter shall have been issued to the Warrantholder at its request by the staff
of the SEC or a ruling shall have been issued to the Warrantholder at its
request by the SEC stating that no action shall be recommended by such staff or
taken by the SEC, as the case may be, if such security is transferred without
registration under the 1933 Act in accordance with the method of disposition and
other conditions set forth in such letter or ruling and such letter or ruling
specifies that no subsequent restrictions on transfer are required. Whenever the
restrictions imposed hereunder shall terminate, as hereinabove provided, the
Warrantholder or holder of a share of Common Stock then outstanding as to which
such restrictions have terminated shall be entitled to receive from the Company,
without expense to such holder, one or more new certificates for this Agreement
or for such shares of Common Stock not bearing any restrictive legend.

            (d) Financial Risk. The Warrantholder has such knowledge and
experience in financial and business matters as to be capable of evaluating the
merits and risks of its investment, and has the ability to bear the economic
risks of its investment.

            (e) Risk of No Registration. The Warrantholder understands that the
Company does not have any class of equity securities registered under Section 12
of the 1934 Act and acknowledges that if the Company does not register a class
of equity securities with the SEC pursuant to Section 12 of the 1934 Act, or
file reports pursuant to Section 15(d) of the 1934 Act, or if a registration
statement covering the securities under the 1933 Act is not in effect when it
desires to sell (i) the rights to purchase Common Stock pursuant to this
Agreement or (ii) the Common Stock issuable upon exercise of the right to
purchase, it may be required to hold such securities for an indefinite period.
The Warrantholder further acknowledges that neither this Agreement nor any other
agreement between the Company and the Warrantholder imposes any obligation on
the Company to file a registration statement under the 1933 Act or to register a
class of equity securities or file reports under the 1934 Act. The Warrantholder
also understands that any sale of (A) its rights hereunder to purchase Common
Stock or (B) Common Stock issued or issuable hereunder which might be made by it
in reliance upon Rule 144 may be made only in accordance with the terms and
conditions of that Rule, including the requirement that there be "current public
information" within the meaning of Rule 144 available with respect to the
Company.

            (f) Accredited Investor. Warrantholder is an "accredited investor"
within the meaning of the Securities and Exchange Rule 501 of Regulation D, as
presently in effect.

            (g) Legend. Warrantholder agrees that the certificates evidencing
any Common Stock issued upon exercise of this Warrant may be stamped or
imprinted with a legend substantially to the following effect:

                                       7

<PAGE>

            THE COMMON STOCK EVIDENCED BY THIS CERTIFICATE HAS NOT BEEN
      REGISTERED UNDER THE SECURITIES ACT OF 1933 AS AMENDED, OR ANY STATE
      SECURITIES LAWS. SUCH COMMON STOCK MAY NOT BE SOLD, OFFERED FOR SALE,
      PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
      STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY
      TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES
      ACT OF 1933 ACT AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS.

      SECTION 10. TRANSFERS.

      Subject to the terms and conditions contained in Section 9, this Agreement
and all rights hereunder are transferable in whole or in part by the
Warrantholder and any successor transferee, provided, that, prior to an Initial
Public Offering, the Company's written consent shall be required for any
transfer requested or proposed by the Warrantholder, which consent may be
granted or withheld at the election of the Company and in its sole
discretionary. The transfer shall be recorded on the books of the Company upon
receipt by the Company of a notice of transfer in the form attached hereto as
Exhibit III (the "Transfer Notice"), at its principal offices and the payment to
the Company of all transfer taxes and other governmental charges imposed on such
transfer.

      SECTION 11. MISCELLANEOUS.

            (a) Effective Date. The provisions of this Agreement shall be
construed and shall be given effect in all respects as if it had been executed
and delivered by the Company on October 1, 2004 with respect to 14,952 shares
issuable upon exercise hereof and on January 1, 2005 with respect to the
remaining 14,952 shares issuable upon exercise hereof. This Agreement shall be
binding upon any successors or assigns of the Company.

            (b) Severability. In the event any one or more of the provisions of
this Agreement shall for any reason be held invalid, illegal or unenforceable,
the remaining provisions of this Agreement shall be unimpaired, and the invalid,
illegal or unenforceable provision shall be replaced by a mutually acceptable
valid, legal and enforceable provision, which comes closest to the intention of
the parties underlying the invalid, illegal or unenforceable provision.

            (c) Notices. Except as otherwise provided herein, any notice,
demand, request, consent, approval, declaration, service of process or other
communication that is required, contemplated, or permitted under this Agreement
or with respect to the subject matter hereof shall be in writing, and shall be
deemed to have been validly served, given, delivered, and received upon the
earlier of: (i) the first business day after transmission by facsimile or hand
delivery or deposit with an overnight express service or overnight mail delivery
service; or (ii) the third calendar day after deposit in the United States
mails, with proper first class postage prepaid, and shall be addressed to the
party to be notified as follows:

                                       8
<PAGE>
            If to Warrantholder:

                  Asante Partners LLC
                  350 Park Avenue, 11th Floor
                  New York, NY 10022
                  Attention:  Frank J. Manzella
                  Telephone:  212-521-1462
                  Facsimile:  212-421-5193

            (i)  If to the Company:

                  OMRIX BIOPHARMACEUTICALS, INC.
                  630 Fifth Avenue, 22nd Floor
                  New York, NY 10111
                  Attention:  Mike Burshtine
                  Telephone:  212-887-6500
                  Facsimile:  212-887-6550

            or to such other address as each party may designate for itself
by like notice.

            (d) Entire Agreement; Amendments. This Agreement constitutes the
entire agreement and understanding of the parties hereto in respect of the
subject matter hereof, and supersedes and replaces in its entirety any prior
agreements, proposals, term sheets, letters, negotiations or other documents,
whether written or oral, with respect to the subject matter hereof (including
the Warrant Agreement between the Company and the Warrantholder, dated March 31,
2005 and Warrantholder's proposal letter dated February 16, 2005). None of the
terms of this Agreement may be amended except by an instrument executed by each
of the parties hereto.

            (e) Headings. The various headings in this Agreement are inserted
for convenience only and shall not affect the meaning or interpretation of this
Agreement or any provisions hereof.

            (f) No Waiver. No omission or delay by either party at any time to
enforce any right or remedy reserved to it, or to require performance of any of
the terms, covenants or provisions hereof by the other party at any time
designated, shall be a waiver of any such right or remedy to which such party is
entitled, nor shall it in any way affect the right of such party to enforce such
provisions thereafter.

            (g) Survival. All agreements, representations and warranties
contained in this Agreement or in any document delivered pursuant hereto shall
survive the execution and delivery of this Agreement and the expiration or other
termination of this Agreement.

            (h) Governing Law. This Agreement shall be governed by, and
construed and enforced in accordance with, the laws of the State of Delaware,
excluding conflict of laws principles that would cause the application of laws
of any other jurisdiction.

                                       9
<PAGE>

            (i) Consent to Jurisdiction and Venue. All judicial proceedings
arising in or under or related to this Agreement may be brought in any state or
federal court of competent jurisdiction located in the State of New York.

            (j) Counterparts. This Agreement and any amendments, waivers,
consents or supplements hereto may be executed in any number of counterparts,
and by different parties hereto in separate counterparts, each of which when so
delivered shall be deemed an original, but all of which counterparts shall
constitute but one and the same instrument.

                  [Remainder of Page Intentionally Left Blank]

                                       10
<PAGE>

      IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed by its officers thereunto duly authorized as of the date first written
above.

                                    COMPANY:
                                    OMRIX BIOPHARMACEUTICALS, INC.

                                    By: /s/ Philippe Romagnoli
                                        --------------------------------
                                        Title:  Secretary General

                                    WARRANTHOLDER:
                                    ASANTE PARTNERS LLC

                                    By: /s/ Authorized Signatory
                                        --------------------------------
                                        Title:   Managing Director

                                       11
<PAGE>

                                    EXHIBIT I
                               NOTICE OF EXERCISE

To:  Omrix Biopharmaceuticals, Inc.

(1)   The undersigned Warrantholder hereby elects to purchase [_______]
      shares of the Common Stock of Omrix Biopharmaceuticals, Inc., pursuant
      to the terms of the Agreement dated as of March [  ], 2006 (the
      "Agreement") between Omrix Biopharmaceuticals, Inc. and the
      Warrantholder, and:

      [    ]      Option One:  Makes payment herewith in full therefor at the
      price per share provided by such Agreement.  Payment of the Purchase
      Price, together with all applicable transfer taxes, if any, shall be
      made by delivery of $_________ transmitted herewith by check; or

      [    ]      Option Two:  Hereby elects to exchange such Warrant
      pursuant to the Cashless Exercise provisions of the Warrant.

(2)   In exercising its rights to purchase the Common Stock of Omrix
      Biopharmaceuticals, Inc., the undersigned hereby confirms and acknowledges
      the investment representations and warranties made in Section 9 of the
      Agreement.

(3)   Please issue a certificate or certificates representing said shares of
      Common Stock in the name of the undersigned or in such other name as is
      specified below.

                                    ------------------------------------
                                    (Name)

                                    ------------------------------------
                                    (Address)

                                    WARRANTHOLDER:
                                    ASANTE PARTNERS LLC

                                    By:
                                       ---------------------------------
                                          Title:
                                                ------------------------
                                          Date:
                                                ------------------------

                                       12
<PAGE>

                                   EXHIBIT II
                           ACKNOWLEDGMENT OF EXERCISE

      The undersigned Omrix Biopharmaceuticals, Inc., hereby acknowledge receipt
of the "Notice of Exercise" from Asante Partners LLC, to purchase [____] shares
of the Common Stock of [_________________], pursuant to the terms of the
Agreement, and further acknowledges that [______] shares remain subject to
purchase under the terms of the Agreement.

                                    COMPANY:
                                    OMRIX BIOPHARMACEUTICALS, INC.

                                    By:
                                       ---------------------------------
                                          Title:
                                                ------------------------
                                          Date:
                                                ------------------------

                                       13
<PAGE>

                                   EXHIBIT III
                                 TRANSFER NOTICE

(To transfer or assign the foregoing Agreement, execute this form and supply
required information. Do not use this form to purchase shares.)

FOR VALUE RECEIVED, the foregoing Agreement and all rights evidenced thereby
are hereby transferred and assigned to

--------------------------------------------------------------------------------
(Please Print)

whose address is
                 ---------------------------------------------------------------
                              Dated:
                                    --------------------------------------------

                              Holder's Signature:
                                                 -------------------------------
                              Holder's Address:
                                               ---------------------------------

Signature Guaranteed:
                     -----------------------------------------------------------

NOTE: The signature to this Transfer Notice must correspond with the name as it
appears on the face of the Agreement, without alteration or enlargement or any
change whatever. Officers of corporations and those acting in a fiduciary or
other representative capacity should file proper evidence of authority to assign
the foregoing Agreement.

                                       14
<PAGE>

                                   EXHIBIT IV
                        OMRIX BIOPHARMACEUTICALS, INC.
                       STOCKHOLDER INSTRUMENT OF ACCESSION

      The undersigned, ___________________, as a condition precedent to becoming
the owner or holder of record of _______________ (_________) shares of Common
Stock, par value $0.01 per share, of Omrix Biopharmaceuticals, Inc., a Delaware
corporation (the "Company"), hereby agrees to become a Stockholder under that
certain Stockholders' Agreement dated as of January 13, 2005 by and among the
Company and the Common Stockholders named therein, as the same as may be amended
from time to time, including by accession of additional parties. This Instrument
of Accession shall take effect and shall become an integral part of, and the
undersigned shall become a party to and bound by, said Stockholders' Agreement
immediately upon execution and delivery to the Company of this Instrument.

      IN WITNESS WHEREOF, this INSTRUMENT OF ACCESSION has been duly executed by
or on behalf of the undersigned as of the date below written.

                                    [NAME]

                                    By:
                                       -----------------------------------------
                                    Name:
                                         ---------------------------------------
                                    Title:
                                          --------------------------------------
                                    Record Address:
                                                   -----------------------------

                                    --------------------------------------------
                                    Telephone No.:
                                                  ------------------------------
                                    Facsimile No.:
                                                  ------------------------------
                                    E-mail Address:
                                                   -----------------------------

                                    ACCEPTED:
                                    OMRIX BIOPHARMACEUTICALS, INC.

                                    By:
                                       -----------------------------------------
                                    Name:
                                         ---------------------------------------
                                    Title:
                                          --------------------------------------
                                    Date:
                                         ---------------------------------------

                                       15<PAGE>
                                                                   EXHIBIT 10.19

                                     FORM OF
                            INDEMNIFICATION AGREEMENT

      This Indemnification Agreement ("Agreement") is made as of
__________________, 20__, by and between Omrix Biopharmaceuticals, Inc., a
Delaware corporation (along with any entities referred to in Section 2(c) below,
the "Company"), and [NAME OF DIRECTOR] ("Director").

                                    RECITALS

      WHEREAS, highly competent persons have become more reluctant to serve
publicly-held corporations as directors or in other capacities unless they are
provided with adequate protection through insurance or adequate indemnification
against inordinate risks of claims and actions against them arising out of their
service to and activities on behalf of the corporation.

      WHEREAS, the Board of Directors of the Company (the "Board") has
determined that, in order to attract and retain qualified individuals as members
of the Board, the Company will attempt to maintain on an ongoing basis, at its
sole expense, liability insurance to protect persons serving the Company and its
subsidiaries from certain liabilities. Although the furnishing of such insurance
has been a customary and widespread practice among United States based
corporations and other business enterprises, the Company believes that, given
current market conditions and trends, such insurance may be available to it in
the future only at higher premiums and with more exclusions. At the same time,
directors are being increasingly subjected to expensive and time-consuming
litigation relating to the business and affairs of corporations. The Company
recognizes that the cost of defending and otherwise participating in such
litigation is far greater than the financial benefits of serving as a Director.
Article Seventh of the Second Amended and Restated Certificate of Incorporation
of the Company and the Delaware General Corporation Law ("DGCL") expressly
provide that the indemnification provisions set forth therein are not exclusive
and contemplate that agreements may be entered into between the Company and
members of the Board (or parties serving at the request of the Board) with
respect to indemnification;

      WHEREAS, the uncertainties relating to insurance have increased the
difficulty of attracting and retaining directors;

      WHEREAS, the Board has determined that the increased difficulty in
attracting and retaining directors is detrimental to the best interests of the
Company's stockholders;

      WHEREAS, it is reasonable, prudent and necessary for the Company
contractually to obligate itself to indemnify, and to pay expenses on behalf of
directors to the fullest extent permitted by applicable law so that they will
serve or continue to serve the Company free from undue concern that they will
not be so indemnified;

      WHEREAS, this Agreement is in furtherance of the Second Amended and
Restated Certificate of Incorporation of the Company, its Amended and Restated
Bylaws

<PAGE>

and any resolutions adopted pursuant thereto, and the DGCL, and shall not be
deemed a substitute therefor, nor to diminish or abrogate any rights of Director
thereunder;

      WHEREAS, the Company has entered into this Agreement and assumed the
obligations imposed on it hereby in order to induce Director to serve as a
director or officer of the Company, and the Company acknowledges that Director
is relying upon this Agreement in serving as a director or officer of the
Company; and

      WHEREAS, Director is willing to serve, continue to serve and to take on
additional service for or on behalf of the Company on the condition that he be
so indemnified;

      NOW, THEREFORE, in consideration of the promises and the covenants
contained herein, the Company and Director do hereby covenant and agree as
follows:

1. SERVICES TO THE COMPANY. Director will serve or continue to serve, at the
will of the Company and its stockholders for so long as Director is duly elected
or appointed or until Director tenders his or her resignation.

2. DEFINITIONS. As used in this Agreement:

      (a) "Beneficial Owner" shall have the meaning given to such term in Rule
13d-3 under the Securities Exchange Act of 1934.

      (b) A "Change in Control" shall be deemed to occur upon the earliest to
occur after the date of this Agreement of any of the following events:

            (i) Acquisition of Stock by Third Party. Any Person (as defined
below) is or becomes the Beneficial Owner, directly or indirectly, of securities
of the Company representing fifteen percent (15%) or more of the combined voting
power of the Company's then outstanding securities;

            (ii) Change in Board of Directors. During any period of two (2)
consecutive years (not including any period prior to the execution of this
Agreement), individuals who at the beginning of such period constitute the Board
(together with any new directors whose election to the Board or whose nomination
for election by the stockholders of the Company was approved by a vote of a
majority of the directors then still in office who were either directors at the
beginning of such period or whose election or nomination for election was
previously so approved) cease for any reason to constitute at least a majority
of the members of the Board;

            (iii) Corporate Transactions. The effective date of a merger or
consolidation of the Company with any other entity, unless such merger or
consolidation would result in the voting securities of the Company outstanding
immediately prior to such merger or consolidation continuing to represent
(either by remaining outstanding or by being converted into voting securities of
the surviving entity, including the parent corporation of such surviving entity)
at least 50% of the total voting power of the voting securities of the surviving
entity outstanding immediately after such merger or

                                       2
<PAGE>

consolidation and with the power to elect at least a majority of the board of
directors or other governing body of such surviving entity;

            (iv) Liquidation. The approval by the stockholders of the Company of
a complete liquidation of the Company or an agreement for the sale or
disposition by the Company of all or substantially all of the Company's assets;
and

            (v) Other Events. There occurs any other event of a nature that
would be required to be reported in response to Item 6(e) of Schedule 14A of
Regulation 14A (or a response to any similar item on any similar schedule or
form) promulgated under the Exchange Act (as defined below), whether or not the
Company is then subject to such reporting requirement.

      (c) "Company" shall include, in addition to Omrix Biopharmaceuticals,
Inc., any corporation, partnership, joint venture, limited liability company,
trust or other enterprise of which such Director is or was serving as a
director, officer, employee or agent of at the request of the Company, or any
corporation which results from or survives a consolidation or merger with Omrix
Biopharmaceuticals, Inc. as well as any corporation resulting from a
consolidation or merger which, if its separate existence had continued, would
have had power and authority to indemnify its directors, officers, employees or
agents, so that if Director is or was a director, officer, employee or agent of
such constituent corporation, or is or was serving at the request of such
constituent corporation as a director, officer, employee or agent of another
corporation, partnership, joint venture, limited liability company, trust or
other enterprise, Director shall stand in the same position under the provisions
of this Agreement with respect to the resulting or surviving corporation as
Director would have with respect to such constituent corporation if its separate
existence had continued.

      (d) "Disinterested Director" means a director of the Company who is not
and was not a party to the Proceeding as defined herein in respect of which
indemnification is sought by Director.

      (e) "Enterprise" shall mean the Company and any other corporation,
partnership, limited liability company, joint venture, trust, employee benefit
plan or other enterprise of which Director is or was serving at the request of
the Company as a director, officer, employee, agent or fiduciary.

      (f) "Exchange Act" shall mean the Securities Exchange Act of 1934, as
amended.

      (g) "Expenses" shall include all reasonable attorneys' and accountants'
fees, retainers, court costs, transcript costs, fees of experts, witness fees,
travel expenses, duplicating costs, printing and binding costs, telephone
charges, postage, delivery service fees, and all other disbursements or expenses
of the types customarily incurred in connection with prosecuting, defending,
preparing to prosecute or defend, investigating, being or preparing to be a
witness in, or otherwise being involved with, a Proceeding as defined in this
Agreement. Expenses also shall include Expenses incurred in connection

                                       3
<PAGE>

with any appeal resulting from any Proceeding, including without limitation the
premium, security for, and other costs relating to any cost bond, supersedeas
bond, or other appeal bond or its equivalent. Expenses, however, shall not
include amounts paid in settlement by Director or the amount of judgments or
fines against Director.

      (h) "Independent Counsel" means a law firm, or a member of a law firm,
that is experienced in matters of corporation law and neither presently is, nor
in the past five years has been, retained to represent: (i) the Company or
Director in any matter material to either such party or (ii) any other party to
the Proceeding giving rise to a claim for indemnification hereunder.
Notwithstanding the foregoing, the term "Independent Counsel" shall not include
any person who, under the applicable standards of professional conduct then
prevailing, would have a conflict of interest in representing either the Company
or Director in an action to determine Director's rights under this Agreement.

      (i) "Person" shall have the meaning as set forth in Sections 13(d) and
14(d) of the Exchange Act; provided, however, that Person shall exclude (i) the
Company or a person or entity that directly or indirectly controls, is
controlled by, or is under common control with, the Company, (ii) any trustee or
other fiduciary holding securities under an employee benefit plan of the
Company, and (iii) any corporation owned, directly or indirectly, by the
stockholders of the Company in substantially the same proportions as their
ownership of stock of the Company.

      (j) The term "Proceeding" shall include any threatened, pending or
completed action, suit, arbitration, alternate dispute resolution mechanism,
investigation (including but not limited to any internal corporate
investigation), inquiry, administrative hearing or any other actual, threatened
or completed proceeding, including any and all appeals, whether brought in the
right of the Company or otherwise and whether of a civil, criminal,
administrative or investigative nature, in which Director was, is, or will be a
party to, a witness in or otherwise participates in by reason of the fact that
Director is or was a director or officer of the Company, by reason of any action
taken by him or of any action on his part while acting as director or officer of
the Company, or by reason of the fact that he is or was serving at the request
of the Company as a director, officer, employee or agent of another Enterprise,
in each case whether or not serving in such capacity at the time any liability
or expense is incurred for which indemnification, reimbursement, or payment of
expenses can be provided under this Agreement; except one initiated by a
Director to enforce his rights under this Agreement. Any Director serving, in
any capacity, (i) another corporation of which a majority of the shares entitled
to vote in the election of its directors is held by the Company, or (ii) any
employee benefit plan of the Company or of any corporation referred to in clause
(i), shall be deemed to be doing so at the request of the Company.

      (k) References to "fines" shall include, but are not limited to, any
excise tax assessed with respect to any employee benefit plan; references to
"serving at the request of the Company" shall include any service as a director,
officer, employee or agent of the Company which imposes duties on, or involves
services by, such director, officer, employee or agent with respect to an
employee benefit plan, its participants or beneficiaries; and a person who acted
in good faith and in a manner he reasonably

                                       4
<PAGE>

believed to be in the best interests of the participants and beneficiaries of an
employee benefit plan shall be deemed to have acted in a manner "not opposed to
the best interests of the Company" as referred to in this Agreement.

3. INDEMNITY IN THIRD-PARTY PROCEEDINGS. A Third-Party Proceeding is a
Proceeding other than a Proceeding by or in the right of the Company to procure
a judgment in its favor. The Company shall indemnify Director in accordance with
the provisions of this Section 3 if Director is, or is threatened to be made, a
party to, a witness in or otherwise participates in any Third-Party Proceeding.
Pursuant to this Section 3, Director shall be indemnified against all Expenses,
judgments, fines and amounts paid in settlement actually and reasonably incurred
by Director or on his behalf in connection with such Third-Party Proceeding or
any claim, issue or matter therein, if Director acted in good faith and in a
manner Director reasonably believed to be in or not opposed to the best
interests of the Company and, in the case of a criminal proceeding had no
reasonable cause to believe that such conduct was unlawful.

4. INDEMNITY IN PROCEEDINGS BY OR IN THE RIGHT OF THE COMPANY. The Company shall
indemnify Director in accordance with the provisions of this Section 4 if
Director is, or is threatened to be made, a party to, a witness in or otherwise
participates in any Proceeding by or in the right of the Company to procure a
judgment in its favor. Pursuant to this Section 4, Director shall be indemnified
against all Expenses actually and reasonably incurred by him or on his behalf in
connection with such Proceeding or any claim, issue or matter therein and to the
extent permitted by law, amounts paid in settlement, if Director acted in good
faith and in a manner he reasonably believed to be in or not opposed to the best
interests of the Company. No indemnification for Expenses shall be made under
this Section 4 in respect of any claim, issue or matter as to which Director
shall have been finally adjudged by a court to be liable to the Company, unless
and only to the extent that the Delaware Court of Chancery or any court in which
the Proceeding was brought shall determine upon application that, despite the
adjudication of liability but in view of all the circumstances of the case,
Director is fairly and reasonably entitled to indemnification.

5. INDEMNIFICATION FOR EXPENSES OF A PARTY WHO IS WHOLLY OR PARTLY SUCCESSFUL.

      (a) In any Proceeding referred to in Section 4, if Director is not wholly
successful in such Proceeding, but has been adjudged to be liable to the Company
as to one or more but less than all claims, issues or matters in such
Proceeding, no indemnification shall be made in respect of any claim, issue or
matter as to which Director shall have been adjudged to be liable to the
Company, unless and only to the extent that the Delaware Court of Chancery or
any court in which the Proceeding was brought shall determine upon application
that, despite the adjudication of liability to the Company, in view of all the
circumstances of the case, Director is fairly and reasonably entitled to such
indemnification. However, in any Proceeding referred to in Section 4, the
Company shall indemnify Director against all Expenses actually and reasonably
incurred by him or on his behalf and, to the extent permitted by law, amounts
paid in settlement, in connection with each claim, issue or matter as to which
Director is successful on the merits or has reached a settlement.

                                       5
<PAGE>

      (b) To the extent that Director has been successful on the merits or
otherwise in defense of any Proceeding (including any Proceeding referred to in
Section 4), or in defense of any claim, issue or matter therein, Director shall
be indemnified and held harmless by the Company to the fullest extent authorized
by the DGCL, as the same exists or may hereafter be amended, against all
Expenses actually and reasonably incurred or suffered by Director or on
Director's behalf in connection therewith. Indemnification pursuant to this
Section 5(b) shall not require a determination pursuant to Section 10 of this
Agreement.

      (c) For purposes of this Section 5 and without limitation, the termination
of any claim, issue or matter in a Proceeding in which Director is a defendant
by dismissal, with or without prejudice, shall be deemed to be a successful
result as to such claim, issue or matter.

6. ADDITIONAL INDEMNIFICATION.

      (a) Notwithstanding any limitation in Sections 3, 4, or 5, the Company
shall indemnify Director to the extent permitted by law if Director is a party
to or threatened to be made a party to, a witness in or otherwise participates
in any Proceeding against all Expenses, judgments, fines and amounts paid in
settlement actually and reasonably incurred by Director in connection with the
Proceeding (1) unless Director's conduct constitutes a breach of Director's duty
of loyalty to the Company or its stockholders, (2) except for liability for acts
or omissions not in good faith or which involve intentional misconduct or a
knowing violation of law, (3) except for liability under Section 174 of the
DGCL, or (4) except for liability relating to any transaction from which the
Director derived an improper benefit.

      (b) For purposes of Section 6(a), the meaning of the phrase "to the extent
permitted by law" shall mean:

            (i) the fullest extent permitted by the provision of the DGCL that
authorizes or contemplates additional indemnification by agreement, or the
corresponding provision of any amendment to or replacement of the DGCL; and

            (ii) the fullest extent authorized or permitted by any amendments to
or replacements of the DGCL adopted after the date of this Agreement that
increase the extent to which a corporation may indemnify its officers and
directors.

7. EXCLUSIONS. Notwithstanding any provision in this Agreement, the Company
shall not be obligated under this Agreement to make any payment for indemnity
including Expenses, judgments, fines and amounts paid in settlement to the
extent that the amount for which Director seeks indemnification, or a portion
thereof:

      (a) has actually been made to or on behalf of Director under any insurance
policy, contract, agreement or otherwise; or

                                       6
<PAGE>

      (b) is based upon an accounting of profits made from the purchase and sale
(or sale and purchase) by Director of securities of the Company in violation of
Section 16(b) of the Exchange Act or similar provisions of state statutory law
or common law; or

      (c) in connection with any Proceeding (or any part of any Proceeding)
initiated or brought voluntarily by Director, including any Proceeding (or any
part of any Proceeding) initiated by Director against the Company or its
directors, officers or employees, unless (i) the Board authorized the Proceeding
(or any part of any Proceeding) prior to its initiation or (ii) the Company
provides the indemnification, in its sole discretion, pursuant to the powers
vested in the Company under applicable law.

8. NOTIFICATION OF INDEMNIFIABLE CLAIM. Director shall, as a condition precedent
to his right to be indemnified under this Agreement, give the Company notice in
writing as soon as practicable of any claim made against Director for which
indemnification will or could be sought under this Agreement. Director agrees
promptly to notify the Company in writing upon being served with any summons,
citation, subpoena, complaint, indictment, information or other document
relating to any Proceeding or matter which will or could be subject to
indemnification or payment of Expenses covered hereunder. The Secretary of the
Company shall, promptly upon receipt of such notice, advise the Board in writing
of such notice. The failure of Director to timely notify the Company shall not
relieve the Company of any obligation which it may have to the Director under
this Agreement or otherwise, unless such failure to provide timely notice
materially prejudices the Company. The omission to notify the Company will not
relieve the Company from any liability for indemnification which it may have to
Director otherwise than under this Agreement.

9. PAYMENT OF EXPENSES. Without regard to Director's ultimate entitlement to
indemnification under other provisions of this Agreement, the Company shall pay
the Expenses as incurred by Director or reimburse Director for his payment of
such Expenses in connection with any Proceeding within thirty (30) days after
the receipt by the Company of a written request for payment of expenses. If the
DGCL so requires, payment of Expenses by the Company under this Section 9 shall
be made only upon delivery to the Company of an undertaking ("Undertaking"). The
Undertaking shall constitute the Director's agreement that: (i) he shall repay
the Expenses paid by the Company to the extent that it is ultimately determined
by final judicial decision from which there is no further right to appeal that
the Director is not entitled to be indemnified by the Company; and (ii) that in
consideration for the payment of such expenses, the Company may, at its sole
discretion, select counsel for Director, assume the defense or otherwise
participate in the defense of such Proceeding. Payment of Expenses pursuant to
this Section shall be unsecured and interest free. Payment of Expenses shall be
made without regard to Director's ability to repay the expenses and without
regard to Director's ultimate entitlement to indemnification under the other
provisions of this Agreement. Such payment shall include any and all reasonable
Expenses incurred pursuing an action to enforce this right of payment of
Expenses, including Expenses incurred preparing and forwarding statements to the
Company to support the payment claimed. This Section 9 shall not apply to any
claim for Expenses made by Director for which indemnity is excluded pursuant to
Section 7. Notwithstanding anything else contained in this Section

                                       7
<PAGE>

9, to the extent that the Company is prohibited by applicable law from making
payment of Expenses to the Director prior to the Company's determination that
the Director is entitled to indemnification, the Company shall not pay Expenses
to the Director pursuant to this Section. Nothing herein shall be construed to
limit the Company's right to seek damages from the Director, including but not
limited to the full amount of the Expenses paid by the Company hereunder. The
selection by the Company of defense counsel for the Director in connection with
any Proceeding, shall be made only with the approval of the Director, which
approval shall not be unreasonably withheld, upon the delivery to Director of
written notice of the Company's election to do so. After delivery of such
notice, approval of such counsel by Director and the retention of such counsel
by the Company, the Company will not be liable to Director under this Agreement
for any fees of counsel subsequently incurred by Director with respect to the
same Proceeding, provided that (i) Director shall have the right to employ his
counsel in any such Proceeding at Director's expense; and (ii) if (A) the
employment of counsel by Director has been previously authorized by the Company,
(B) Director shall have reasonably concluded that there may be a conflict of
interest between the Company and Director in the conduct of any such defense, or
(C) the Company shall not, in fact, have employed counsel to assume the defense
of such Proceeding, then the fees and expenses of Director's counsel shall be at
the expense of the Company.

10. PROCEDURE UPON APPLICATION FOR INDEMNIFICATION.

      (a) Upon final disposition of a Proceeding for which indemnification is
sought pursuant to Section 3 or Section 4, Director shall submit promptly (and
in any event, no later than the applicable statute of limitations) to the Board
a written request for indemnification averring that he has met the applicable
standard of conduct set forth herein. Any indemnification made under this
Agreement pursuant to Section 3 or Section 4 shall be made by the Company only
as authorized in the specific case upon a determination that indemnification of
the Director is proper in the circumstances because Director has met the
applicable standard of conduct. Such determination shall be made in the
following manner: (i) if a Change in Control shall have occurred and the
Director is not a director at the time of such determination, by Independent
Counsel in a written opinion to the Board, a copy of which shall be delivered to
Director; and (ii) in any other circumstance: (A) by a majority vote of the
Disinterested Directors, even though less than a quorum of the Board, (B) by a
committee of Disinterested Directors designated by a majority vote of the
Disinterested Directors, even though less than a quorum of the Board, (C) if
there are no such Disinterested Directors or, if such Disinterested Directors so
direct, by Independent Counsel in a written opinion to the Board, a copy of
which shall be delivered to Director or (D) if so directed by the Board, by the
stockholders of the Company, and, if it is so determined that Director is
entitled to indemnification, payment to Director shall be made within thirty
(30) days after such determination. Director shall cooperate with the person,
persons or entity making such determination with respect to Director's
entitlement to indemnification, including providing to such person, persons or
entity upon reasonable advance request any documentation or information which is
not privileged or otherwise protected from disclosure and which is reasonably
available to Director and reasonably necessary to such determination. Any costs
or expenses (including attorneys' fees and disbursements) incurred by Director
in so cooperating with

                                       8
<PAGE>

the person, persons or entity making such determination shall be borne by the
Company (irrespective of the determination as to Director's entitlement to
indemnification) and the Company hereby indemnifies and agrees to hold Director
harmless therefrom.

      (b) In the event the determination of entitlement to indemnification is to
be made by Independent Counsel pursuant to Section 10(a) hereof, the Independent
Counsel shall be selected as provided in this Section 10(b). If a Change in
Control shall not have occurred, the Independent Counsel shall be selected by
the Board within ten (10) days of submission of a written request by Director
for indemnification pursuant to Section 10(a), and the Company shall give
written notice to Director advising him of the identity of the Independent
Counsel so selected. If a Change in Control shall have occurred, the Independent
Counsel shall be selected by Director within ten (10) days of submission of a
written request by Director for indemnification pursuant to Section 10(a),
(unless Director shall request that such selection be made by the Board, in
which event the preceding sentence shall apply), and Director shall give written
notice to the Company advising it of the identity of the Independent Counsel so
selected. In either event, Director or the Company, as the case may be, may,
within ten (10) days after such written notice of selection shall have been
given, deliver to the Company or to Director, as the case may be, a written
objection to such selection; provided, however, that such objection may be
asserted only on the ground that the Independent Counsel so selected does not
meet the requirements of "Independent Counsel" as defined in Section 2 of this
Agreement, and the objection shall set forth with particularity the factual
basis of such assertion. The objection must also include a proposed substitute
Independent Counsel. If objection including a proposed substituted Independent
Counsel is timely made, such substituted Independent Counsel shall serve as
Independent Counsel unless objected to within ten (10) days. An objection to the
substituted Independent Counsel may be asserted only on the ground that the
Independent Counsel so selected does not meet the requirements of "Independent
Counsel" as defined in Section 2 of this Agreement, and the objection shall set
forth with particularity the factual basis of such assertion. If written
objection is made, the Independent Counsel or substituted Independent Counsel
proposed may not serve as Independent Counsel unless and until such objection is
withdrawn or a court has determined that such objection is without merit. If,
within thirty (30) days after submission by Director of a written request for
indemnification pursuant to Section 10(a) hereof, the parties have not agreed
upon the selection of the Independent Counsel, either the Company or Director
may petition a court of competent jurisdiction for resolution of any objection
which shall have been made by the Company or Director to the other's selection
of Independent Counsel and/or for the appointment as Independent Counsel of a
person selected by the Court or by such other person as the Court shall
designate, and the person with respect to whom all objections are so resolved or
the person so appointed shall act as Independent Counsel under Section 10(a)
hereof.

      (c) In the event of a Change in Control, the Company shall, upon written
request by Director, create a trust for the benefit of Director (the "Trust")
and from time to time upon written request of Director shall fund the Trust in
an amount equal to all Expenses, judgments, fines and amounts paid in settlement
reasonably anticipated at the time to be incurred in connection with any
Proceeding or any claim, issue or matter therein. The amount to be deposited in
the Trust pursuant to the foregoing funding

                                       9
<PAGE>

obligation shall be determined by the party required to make the determination
that indemnification of Director is proper pursuant to Section 10(a) hereof (the
"Reviewing Party"). The terms of the Trust shall provide that (i) the Trust
shall not be revoked or the principal thereof invaded without the written
consent of Director, (ii) the trustee of the Trust shall advance, within thirty
(30) business days of a request by Director, any and all Expenses to Director
(and Director hereby agrees to reimburse the Trust under the circumstances in
which Director would be required to reimburse the Company for any Expenses
advanced under this Agreement), (iii) the Trust shall continue to be funded by
the Company in accordance with the funding obligation set forth above, (iv) the
trustee of the Trust shall promptly pay to Director all amounts for which
Director shall be entitled to indemnification pursuant to this Agreement or
otherwise and (v) all unexpended funds in that Trust shall revert to the Company
upon a final determination by the Reviewing Party or a court of competent
jurisdiction, as the case may be, that Director has received amounts, if any,
which fully satisfy the Company's obligation to indemnify Director under the
terms of this Agreement. The trustee of the Trust shall be chosen by Director.
Nothing in this Section 10(c) shall relieve the Company of any of its
obligations under this Agreement.

11. PRESUMPTIONS AND EFFECT OF CERTAIN PROCEEDINGS.

      (a) The submission of the Application for Indemnification to the Board
shall create a rebuttable presumption that the Director is entitled to
indemnification under this Agreement, and the Board, Independent Counsel, or
stockholders, as the case may be, may, at any time, specifically determine that
the Director is so entitled, unless it or they possess sufficient evidence to
rebut the presumption that Director has met the applicable standard of conduct.
If a determination shall have been made pursuant to this Agreement that Director
is entitled to indemnification, the Company shall be bound by such determination
in any judicial proceeding commenced pursuant to Section 12, absent (i) a
misstatement by Director of a material fact, or an omission of a material fact
necessary to make Director's statement not materially misleading, in connection
with the request for indemnification, or (ii) a prohibition of such
indemnification under applicable law. Neither the failure of the Company
(including by its directors or Independent Counsel) to have made a determination
prior to the commencement of any action pursuant to this Agreement that
indemnification is proper in the circumstances because Director has met the
applicable standard of conduct, nor an actual determination by the Company
(including by its directors or Independent Counsel) that Director has not met
such applicable standard of conduct, shall be a defense to the action or create
a presumption that Director has not met the applicable standard of conduct.
Moreover, the fact that the Company has paid the Director's Expenses pursuant to
Section 9 herein shall not create a presumption that Director has met the
applicable standard of conduct for indemnification.

      (b) The termination of any Proceeding or of any claim, issue or matter
therein, by judgment, order, settlement or conviction, or upon a plea of nolo
contendere or its equivalent, shall not (except as otherwise expressly provided
in this Agreement) of itself adversely affect the right of Director to
indemnification or create a presumption that Director did not act in good faith
and in a manner which he reasonably believed to be in

                                       10
<PAGE>

or not opposed to the best interests of the Company or, with respect to any
criminal Proceeding, that Director had reasonable cause to believe that his
conduct was unlawful.

      (c) For purposes of any determination of good faith, Director shall be
deemed to have acted in good faith if Director's action is based on the advice
of legal counsel for the Company or on information or records given or reports
made to the Company by an independent certified public accountant or by an
appraiser or other expert selected with reasonable care by the Company. The
provisions of this Section 11(d) shall not be deemed exclusive or to limit in
any way the other circumstances in which the Director may be deemed to have met
the applicable standard of conduct set forth in this Agreement.

      (d) To the extent legally permissible, the knowledge and/or actions, or
failure to act, of any director, officer, agent or employee of the Enterprise
shall not be imputed to Director for purposes of determining the right to
indemnification under this Agreement.

12. REMEDIES OF DIRECTOR.

      (a) In the event that (i) a determination is made pursuant to Section 10
of this Agreement that Director is not entitled to indemnification under this
Agreement, (ii) payment of Expenses is not timely made pursuant to Section 9 of
this Agreement, or (iii) payment of indemnification pursuant to Section 3, 4,
5(a) or 6 of this Agreement is not made within thirty (30) days after a
determination has been made that Director is entitled to indemnification,
Director shall be entitled to an adjudication by a court of his entitlement to
such indemnification or payment of Expenses.

      (b) In the event that Director successfully sues the Company for
indemnification or payment of Expenses, and is successful in whole or in part,
Director shall be entitled to be paid by the Company for the Expense of
prosecuting such suit. If the Company sues Director to recover Expenses paid and
Director is successful in defending such suit, in whole or in part, Director
shall be entitled to be paid the Expense of defending such suit.

      (c) In the event that a determination shall have been made under this
Agreement that Director is not entitled to indemnification, any judicial
proceeding commenced pursuant to this Section shall be conducted in all respects
as a de novo trial on the merits and Director shall not be prejudiced by reason
of that adverse determination. In any judicial proceeding pursuant to this
Section, the Company shall have the burden of proving Director is not entitled
to indemnification or payment of Expenses, as the case may be.

      (d) The Company shall be precluded from asserting in any judicial
proceeding commenced pursuant to this Section that the procedures and
presumptions of this Agreement are not valid, binding and enforceable and shall
stipulate in any such court that the Company is bound by all the provisions of
this Agreement. The Company shall indemnify Director against any and all
Expenses and, if requested by Director, shall (within THIRTY (30) days after
receipt by the Company of a written request therefore) pay

                                       11
<PAGE>

such Expenses to Director, which are incurred by Director in connection with any
action brought by Director for indemnification or payment of Expenses from the
Company under this Agreement or under any directors' and officers' liability
insurance policies maintained by the Company, regardless of whether Director
ultimately is determined to be entitled to such indemnification, payment of
Expenses or insurance recovery, as the case may be.

13. NON-EXCLUSIVITY; SURVIVAL OF RIGHTS; INSURANCE; SUBROGATION.

      (a) The rights of indemnification and to receive payment of Expenses as
provided by this Agreement shall not be deemed exclusive of any other rights to
which Director may at any time be entitled under applicable law, the Company's
Second Amended and Restated Certificate of Incorporation, the Company's Amended
and Restated Bylaws, any agreement, a vote of stockholders or a resolution of
directors, or otherwise. No amendment, alteration or repeal of this Agreement or
of any provision hereof shall limit or restrict any right of Director under this
Agreement in respect of any action taken or omitted by such Director prior to
such amendment, alteration or repeal. To the extent that a change in Delaware
law, whether by statute or judicial decision, permits greater indemnification or
payment of Expenses than would be afforded currently under the Company's Second
Amended and Restated Certificate of Incorporation, Amended and Restated Bylaws
and this Agreement, it is the intent of the parties hereto that Director shall
enjoy by this Agreement the greater benefits so afforded by such change. No
right or remedy herein conferred is intended to be exclusive of any other right
or remedy, and every other right and remedy shall be cumulative and in addition
to every other right and remedy given hereunder or now or hereafter existing at
law or in equity or otherwise. The assertion or employment of any right or
remedy hereunder, or otherwise, shall not prevent the concurrent assertion or
employment of any other right or remedy.

      (b) The Company shall, from time to time, make the good faith
determination whether or not it is practicable for the Company to obtain and
maintain a policy or policies of insurance with reputable insurance companies
providing the directors, officers, employees, or agents of the Company with
coverage for losses from wrongful acts, or to ensure the Company's performance
of its indemnification obligations under this Agreement. Among other
considerations, the Company will weigh the costs of obtaining such insurance
coverage against the protection afforded by such coverage. To the extent that
the Company maintains an insurance policy or policies providing liability
insurance for directors of the Company or of any other corporation, partnership,
joint venture, trust, employee benefits plan or other enterprise which the
Director serves at the request of the Company, Director shall be covered by such
policy or policies in such manner as to provide the Director the same rights and
benefits as are accorded to the most favorably insured of the Company's
directors. The Company shall thereafter take all necessary or desirable action
to cause such insurers to pay, on behalf of the Director, all amounts payable as
a result of such proceeding in accordance with the terms of such policies.

      (c) In the event of any payment under this Agreement, the Company shall be
subrogated to the extent of such payment to all of the rights of recovery of
Director, who shall execute all papers required and take all action necessary to
secure such rights,

                                       12
<PAGE>

including execution of such documents as are necessary to enable the Company to
bring suit to enforce such rights.

14. DURATION OF AGREEMENT. This Agreement shall continue until and terminate
upon the later of: (a) 10 years after the date that Director shall have ceased
to serve as a director or officer of the Company or as a director, officer,
employee or agent of any other corporation, partnership, joint venture, limited
liability company, trust, employee benefit plan or other enterprise which
Director served at the request of the Company ("Ten Year Anniversary Date"); or
(b) 1 year after the final termination of each and every Proceeding, commenced
prior to the Ten Year Anniversary Date.

15. SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon the Company and
its successors and assigns and shall inure to the benefit of Director and his
heirs, executors and administrators.

16. SEVERABILITY. If any provision or provisions of this Agreement shall be held
to be invalid, illegal or unenforceable for any reason whatsoever: (a) the
validity, legality and enforceability of the remaining provisions of this
Agreement (including without limitation, each portion of any Section of this
Agreement containing any such provision held to be invalid, illegal or
unenforceable, that is not itself invalid, illegal or unenforceable) shall not
in any way be affected or impaired thereby and shall remain enforceable to the
fullest extent permitted by law; (b) such provision or provisions shall be
deemed reformed to the extent necessary to conform to applicable law and to give
the maximum effect to the intent of the parties hereto; and (c) to the fullest
extent possible, the provisions of this Agreement (including, without
limitation, each portion of any Section of this Agreement containing any such
provision held to be invalid, illegal or unenforceable, that is not itself
invalid, illegal or unenforceable) shall be construed so as to give effect to
the intent manifested thereby.

17. ENTIRE AGREEMENT. Except as otherwise specified herein, this Agreement
constitutes the entire agreement between the parties hereto with respect to the
subject matter hereof and supersedes all prior agreements and understandings,
oral, written and implied, between the parties hereto with respect to the
subject matter hereof.

18. EFFECTIVENESS OF AGREEMENT. This Agreement shall be effective as of the date
set forth on the first page and may apply to acts or omissions of Director which
occurred prior to such date if Director was an officer, director, employee or
other agent of the Company, or was serving at the request of the Company as a
director, officer, employee or agent of another corporation, partnership, joint
venture, limited liability company, trust or other enterprise, at the time such
act or omission occurred, and shall continue to exist after the rescission or
restrictive modification of this Agreement with respect to events occurring
prior to such rescission or restrictive modification.

19. MODIFICATION AND WAIVER. No supplement, modification or amendment of this
Agreement shall be binding unless executed in writing by the parties thereto. No
waiver of any of the provisions of this Agreement shall be deemed or shall
constitute a waiver of

                                       13
<PAGE>

any other provisions of this Agreement nor shall any waiver constitute a
continuing waiver.

20. NOTICES. All notices, requests, demands and other communications under this
Agreement shall be in writing and shall be deemed to have been duly given (a) if
delivered by hand and receipted for by the party to whom said notice or other
communication shall have been directed, or (b) if sent by an overnight courier
service (such as Federal Express):

If to Director, at the address indicated on the signature page of this
Agreement, or such other address as Director shall provide to the Company

      If to the Company, to

            Omrix Biopharmaceuticals, Inc.
            Attention:  Robert Taub, Chief Executive Officer
            630 Fifth Avenue, 22nd Floor
            New York, New York 10111

or to any other address as may have been furnished to Director by the
Company.

21. CONTRIBUTION. To the fullest extent permissible under applicable law, if the
indemnification provided for in this Agreement is unavailable to Director for
any reason whatsoever, the Company, in lieu of indemnifying Director, shall
contribute to the amount incurred by Director, whether for judgments, fines,
penalties, excise taxes, amounts paid or to be paid in settlement and/or for
Expenses, in connection with any claim relating to an indemnifiable event under
this Agreement, in such proportion as is deemed fair and reasonable in light of
all of the circumstances of such Proceeding in order to reflect (i) the relative
benefits received by the Company and Director as a result of the event(s) and/or
transaction(s) giving cause to such Proceeding; and/or (ii) the relative fault
of the Company (and its directors, officers, employees and agents) and Director
in connection with such event(s) and/or transaction(s).

22. APPLICABLE LAW AND CONSENT TO JURISDICTION. This Agreement and the legal
relations among the parties shall be governed by, and construed and enforced in
accordance with, the laws of the State of Delaware, without regard to its
conflict of laws rules. The Company and Director hereby irrevocably and
unconditionally (i) agree that any action or proceeding arising out of or in
connection with this Agreement shall be brought only in the Chancery Court of
the State of Delaware (the "Delaware Court"), and not in any other state or
federal court in the United States of America or any court in any other country,
(ii) consent to submit to the exclusive jurisdiction of the Delaware Court for
purposes of any action or proceeding arising out of or in connection with this
Agreement, (iii) waive any objection to the laying of venue of any such action
or proceeding in the Delaware Court, and (iv) waive, and agree not to plead or
to make, any claim that any such action or proceeding brought in the Delaware
Court has been brought in an improper or inconvenient forum.

                                       14
<PAGE>

23. IDENTICAL COUNTERPARTS. This Agreement may be executed in one or more
counterparts, each of which shall for all purposes be deemed to be an original
but all of which together shall constitute one and the same Agreement. Only one
such counterpart signed by the party against whom enforceability is sought needs
to be produced to evidence the existence of this Agreement.

24. MISCELLANEOUS. Use of the masculine pronoun shall be deemed to include usage
of the feminine pronoun where appropriate. The headings of the paragraphs of
this Agreement are inserted for convenience only and shall not be deemed to
constitute part of this Agreement or to affect the construction thereof.

IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of
the day and year first above written.

----------------------------

By:
    ------------------------

[NAME OF DIRECTOR]

--------------------------

ADDRESS OF DIRECTOR:

--------------------------

--------------------------

--------------------------

--------------------------

                                       15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00100-of-00352.parquet"}]]